Relationship of first-year costs of treating localized prostate cancer to initial choice of therapy and stage at diagnosis: results from the CaPSURE database

Penson, David F.; Schonfeld, Warren H.; Flanders, Scott C.; Henke, Curtis J.; Warolin, Karen L.; Carroll, Peter R.; Litwin, Mark S.

doi:10.1016/s0090-4295(00)01033-5

Cited by 32 publications

(35 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unfortunately, Taplin et al did not report data on health-care utilization so it is difficult to determine the extent to which differences between studies are related to changes in patterns of care. Our results are more consistent with Penson et al 9 despite differences in study designs. Penson et al used a more direct approach in estimating costs by applying Medicare reimbursement rates to medical resource use data from the CaPSURE database and only studied patients with local PCa.…”

Section: Discussionsupporting

confidence: 93%

“…Several studies have been conducted that examine the effect of PCa stage on initial treatment costs with conflicting results. [7][8][9] The majority of costs related to PCa occur during the period of initial treatment. Both Taplin et al 7 and Penberthy et al 8 reported that initial PCa stage did not affect treatment costs whereas Penson et al 9 concluded that first-year costs do increase by stage particularly for patients treated with radical prostatectomy.…”

Section: Introductionmentioning

confidence: 99%

“…[7][8][9] The majority of costs related to PCa occur during the period of initial treatment. Both Taplin et al 7 and Penberthy et al 8 reported that initial PCa stage did not affect treatment costs whereas Penson et al 9 concluded that first-year costs do increase by stage particularly for patients treated with radical prostatectomy. The purpose of this study was to estimate first-year PCa costs and to examine the extent to which costs and utilization vary by initial stage.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

First-year costs of treating prostate cancer: estimates from SEER-Medicare data

Roehrborn

Albertsen

Stokes

et al. 2009

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Pharmacologic therapies are currently being evaluated for the prevention of prostate cancer (PCa). As additional clinical data become available regarding their benefits and risks, an examination of their economic impact will also be important. The purpose of this study was to estimate mean per patient PCa-related costs during the first year following diagnosis and to examine the extent to which initial therapies are used, by initial cancer stage. Our data show that health-care costs were significant and varied by stage. With average first-year PCa-related costs of US$13 091, prevention strategies have the potential to reduce health-care costs.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

First-year costs of treating prostate cancer: estimates from SEER-Medicare data

Roehrborn

Albertsen

Stokes

et al. 2009

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

show abstract

“…Another CaPSURE study only examined first-year costs. 20 Other studies have also looked at the costs of localized prostate cancer using the SEER-Medicare linked database. Burkhardt et al 6 looked at initial treatment costs of radiation therapy and radical prostatectomy, but compared only the short-term costs of 2 treatments.…”

Section: Original Article 5396mentioning

confidence: 99%

How does initial treatment choice affect short‐term and long‐term costs for clinically localized prostate cancer?

Snyder

Frick

Blackford³

et al. 2010

Cancer

View full text Add to dashboard Cite

BACKGROUND. Data regarding costs of prostate cancer treatment are scarce. This study investigates how initial treatment choice affects short-term and long-term costs. METHODS. This retrospective, longitudinal cohort study followed prostate-cancer cases diagnosed in 2000 for 5 years using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. Men age !66 years, in Medicare fee for service, diagnosed with clinically localized prostate cancer in 2000 while residing in a SEER region, were matched to noncancer controls using age, sex, race, region, comorbidity, and survival. On the basis of treatment received during the first 9 months postdiagnosis, patients were assigned to watchful waiting, radiation, hormonal therapy, hormonal þ radiation, and surgery (may have received other treatments). Incremental costs for prostate cancer were the difference in costs for prostate cancer cases versus matched controls. Costs were divided into initial treatment (months À1 to 12), long-term (each 12 months thereafter), and total (months À1 to 60). Sensitivity analyses excluded the last 12 months of life. RESULTS. A total of 13,769 prostate-cancer cases were matched to 13,769 noncancer controls. Watchful waiting had the lowest initial treatment ($4270) and 5-year total costs ($9130). Initial treatment costs were highest for hormonal þ radiation ($17,474) and surgery ($15,197). At $26,896, 5-year total costs were highest for hormonal therapy only followed by hormonal þ radiation ($25,097) and surgery ($19,214). After excluding the last 12 months of life, total costs were highest for hormonal þ radiation ($23,488) and hormonal therapy ($23,199). CONCLUSIONS. Patterns of costs vary widely based on initial treatment. These data can inform patients and clinicians considering treatment options and policy makers interested in patterns of costs. Cancer 2010;116:5391-9.

show abstract

“…Although recent studies have examined PCa-related costs from a Medicare perspective using either the Surveillance, Epidemiology, and End Results (SEER)-Medicare data, [4][5][6] the Medicare 5% public use files, 7 or the CaPSURE database, 8 there are few recent studies examining costs in phases of care beyond initial treatment and stratified by cancer stage. Furthermore, many of the studies identified only examine costs for patients diagnosed with early stage PCa.…”

Section: Introductionmentioning

confidence: 99%

Long-term medical-care costs related to prostate cancer: estimates from linked SEER-Medicare data

Stokes¹,

Black²,

Benedict³

et al. 2010

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Limited data are available concerning long-term prostate cancer (PCa)-related medical costs for use in assessing PCa prevention strategies. The aim of this study was to examine treatment, long-term survival, and long-term PCa-related costs by cancer stage. Costs in phases of care based on the natural history of PCa were also examined. Our data illustrate that initial care is characteristic of a rapid rate of cost accrual. This rate then decreases during continuing care. For terminal care, only stage IV resumes a rate of cost accrual similar to initial care. With average PCa-related costs of $18 168 observed over an average follow-up of 4 years, prevention strategies may result in a reduction in medical costs.

show abstract

Relationship of first-year costs of treating localized prostate cancer to initial choice of therapy and stage at diagnosis: results from the CaPSURE database

Cited by 32 publications

References 8 publications

First-year costs of treating prostate cancer: estimates from SEER-Medicare data

First-year costs of treating prostate cancer: estimates from SEER-Medicare data

How does initial treatment choice affect short‐term and long‐term costs for clinically localized prostate cancer?

Long-term medical-care costs related to prostate cancer: estimates from linked SEER-Medicare data

Contact Info

Product

Resources

About